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mellitus, stroke/transient ischemic attack [TIA] ). However, its introduction posed an important issue on what is the lowest score for OAT initiation. 6 In the absence of risk factors (CHA 2 DS 2 VASc = 0), individuals forego anticoagulation, while in the presence of at least 2 non-genderrelated (NGR) risk factors, anticoagulation is warranted. 3, 7, 8 Even with the results of the more recent studies comparing warfarin with the non-VKA oral anticoagulants (NOACs), the risk-benefit profile of OAC agents in the lowest-risk individuals could not be settled. In fact, these randomized trials did not include individuals with a CHA 2 DS 2 VASc score of 1. These uncertainties are reflected in the guideline recom- ing OAT. The aim of our study was to assess the incidence of stroke and bleeding in an inception cohort of prospectively recorded data of warfarin-treated NVAF individuals with 1 NGR risk factor for stroke.
| METHODS
We used data collected in the START (Survey on anTicoagulated pAtients RegisTer). 12 START is an independent, inception cohort, obser- Endpoints included the incidence of stroke or systemic embolism, Total follow-up time for each individual was calculated as the number of days from the start of OAC until censoring. Individuals were censored when an endpoint occurred, death (from a cause other than a stroke endpoint), or last date of data collection.
| STATISTICS
Rates of events are calculated as events per 100 person-years.
Baseline characteristics are presented as appropriate and compared in individuals who bled versus those who did not using Fisher's exact test. Kaplan-Meier survival analysis was used to determine the cumulative incidence of major bleeding events; data were compared using the Log-rank test for comparison. Cutoff for statistical significance was set at P < .05. The assessed patient characteristics for statistical analysis were patient demographics: age, sex, and single CHA 2 DS 2 VASc and HASBLED risk factors. Baseline characteristics and incidence rates are provided in detail; comparative statistical analysis data are presented in results only in case of significance (P < .05).
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| RESULTS

Starting May 2011 until May 2016, of the 7497 individuals recorded
into the register, 431 (5.7%) fulfilled the extraction criteria. The mean age of the cohort was 63 years, and 160 (37%) were female. Age (65-74 years) was the only thromboembolic risk factor in 187 individuals, while hypertension (n = 223), diabetes (n = 10), congestive heart failure (n = 10), and vascular disease (n = 1) were the single remaining risk factors (n = 244). Mean CHA 2 DS 2 VASc score of the cohort was 1.4, while the mean HASBLED score was 0.9. The clinical characteristics of the studied cohort are illustrated in Table 1 .
The follow-up extended for 604 person-years. During follow-up, 1 nonfatal ischemic stroke was recorded (0.17 per 100 person-years).
The event occurred in a female patient with hypertension as an adjunctive risk factor; her TTR was 42%, and the INR at the time of event was 1.8.
There were 9 major bleeding events (1.49 per 100 person-years) as illustrated in Table 2 . Of the 9 events, 2 occurred in female individuals with hypertension and 7 in males, 5 of which with hypertension and 
74). More bleeding events occurred in individuals
<65 years old as compared to individuals in the 65-74 age-group (7 vs 2, respectively; P = .31). Major bleeding incidence was more frequent among individuals with hypertension (7 vs 2 cases, respectively; P = .17).
There were 4 intracranial hemorrhages (0.66 per 100 personyears) all in male individuals; 1 with age ≥65 and 3 with hypertension as the sole risk factors. On Cox regression, hypertension was the only predictor of major bleeding (HR = 21.9, 95% CI 1.6-400; P = .027).
| DISCUSSION
In this study, we found that in individuals categorized at the lower-risk end of the CHA 2 DS 2 VASc score (CHA 2 DS 2 VASc 1 for males and 2 for females) and treated with warfarin, the rate of major bleeding was is of concern. The reported rate of ICH in the general population is 0.01 per 100 person-years in the <75 year age-group. 22 In the ATRIA study, 23 an NVAF cohort with a mean age of 72 years, the reported rate of ICH in nonanticoagulated individuals was 0.29 per 100 patient-years. In light of these data, anticoagulation conferred a markedly increased risk of ICH in our population (mean age 63 years) of NVAF individuals. Surprisingly, we found more major bleeding and ICH in individuals <65 years old. These data deserve attention, as age 65-74 years is a more powerful ischemic stroke risk factor than the others weighted as 1 on CHA 2 DS 2 VASc score, 2 thus individuals with only 1 of the other factors not only may be below the 1% per year ischemic threshold but may be at higher risk for major and ICH according to our data. Furthermore, our results suggest that another single risk factor, such as hypertension, not only is a "minor" ischemic risk factor but also might significantly expose warfarin-treated individuals to major bleeding. We had also more individuals below 65 years of age experiencing major bleeding. Taken together, these data urge caution in the decision to treat with warfarin individuals with 1 NGR risk factor.
Strengths of the present study lie in its design. First, in contrast to retrospective studies based on data regarding dispensing of medications, the present study suggests a causal relationship rather than temporal association. Second, the gathered information allowed researchers to comment on the clinical importance of the bleeding events, excluding clinically insignificant bleeding with the bleeding outcome data. Third, we could calculate the HASBLED score (which includes labile INR) rather than HASBLED, used in administrative data studies.
Limitation of this study is the relatively low number of individuals assessed, although this population (1 NGR risk factor) is also poorly represented in other NVAF studies. Arguably, the relatively short follow-up might have tipped the balance in favor of the side effects (side effects develop early with the treatment, while complications of the disease may take longer to develop). However, long follow-up is not suitable for this kind of population because NVAF is not a "static"
healthcare state due to changes in risk factors change over time. 24 As time goes by, age and other risk factors develop more frequently; thus, longer follow-up times switch the patients to higher thromboembolic risk category, where anticoagulation would be justified. Under these premises, our relatively shorter follow-up is favorable when assessing this specific (1 NGR risk factor) population.
The major clinical implications of this work are that the risk of bleeding should not be underestimated in younger individuals without significant bleeding risk factors. By treating these individuals with warfarin, not only we had a low impact in ischemic risk, but also a high impact on major bleeding incidence. Our data need confirmation from larger prospective registries, but this study might serve as a pivotal work for further research.
Other robust analysis points against the use of anticoagulation with warfarin in this group of individuals, 10 and our data on major bleeding further support this point. NOACs may be a more suitable treatment option for those at lower stroke risk, but data are still scant, and importantly, this patient group is not represented in the pivotal NOAC trials.
In conclusion, we found an elevated risk of major bleeding and intracranial hemorrhage in NVAF individuals treated with warfarin with 1 NGR risk factor for stroke. These data call for caution when treating with warfarin these individuals. 
